Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 6/20 | 0.44 |
| ▸ | EPAS1 | Q99814 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.38 |
| ▸ | FAAH | O00519 | 1/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22602047 | 0.80 | SMN1; SMN2 (0.44) | SMN1; SMN2PTGS2EPAS1ALDH1A1MAPT | |
| SCHEMBL7412893 | 0.78 | SMN1; SMN2 (0.67) | SMN1; SMN2PTGS2LMNAALDH1A1MAPT | |
| SCHEMBL15656580 | 0.78 | MAPT (0.44) | SMN1; SMN2PTGS2EPAS1ALDH1A1MAPT | |
| SCHEMBL7418349 | 0.78 | SMN1; SMN2 (0.41) | SMN1; SMN2PTGS2EPAS1LMNAPDE4B | |
| SCHEMBL29903387 | 0.76 | SLC6A9 (0.45) | SMN1; SMN2LMNA | |
| SCHEMBL3554918 | 0.75 | SMN1; SMN2 (0.49) | SMN1; SMN2PTGS2LMNAALDH1A1MAPT | |
| SCHEMBL7417584 | 0.74 | PTGDR2 (0.44) | SMN1; SMN2PTGS2 | |
| SCHEMBL6876872 | 0.74 | ALDH1A1 (0.50) | SMN1; SMN2LMNAALDH1A1MAPT | |
| SCHEMBL11697683 | 0.73 | SMN1; SMN2 (0.44) | SMN1; SMN2PTGS2EPAS1LMNAALDH1A1 | |
| SCHEMBL3123667 | 0.73 | SMN1; SMN2 (0.40) | SMN1; SMN2PTGS2LMNAPDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1163214-A1 | GAMMA-KETOACID DIPEPTIDES AS INHIBITORS OF CASPASE-3 | Merck Frosst Canada & Co. (CA) | 2001-12-19 | — | — | EP | disclosed |
| US-6225288-B1 | IMPLICATED IN MODULATING APOPTOSIS; TREATMENT OF:CARDIAC AND CEREBRAL ISCHEMIA/REPERFUSION INJURY, SPINAL CORD INJURY AND ORGAN DAMAGE DURING TRANSPLANTATION, CHRONIC NEURODEGENERATIVE DISEASES, IMMUNODEFICIENCY, DIABETES, ALOPECIA, AGING | MERK FROSST CANADA & CO. (CA) | 2001-05-01 | — | — | US | disclosed |
| WO-2000055127-A1 | GAMMA-KETOACID DIPEPTIDES AS INHIBITORS OF CASPASE-3 | MERCK FROSST CANADA & CO. (CA) | 2000-09-21 | — | — | WO | disclosed |